Global Compounding Chemotherapy Market

Compounding Chemotherapy Comprehensive Study by Type (Pharmaceutical Ingredient Alteration (PIA), Currently Unavailable Pharmaceutical Manufacturing (CUPM), Pharmaceutical Dosage Alteration (PDA)), Delivery Method (Gravimetric Automated Compounding Device (weight-based), Volumetric Automated Compounding Device (volume-based)), Dose (Chemotherapeutic, Non-Chemotherapeutics), Sterility (Sterile, Non-Sterile) Players and Region - Global Market Outlook to 2030

Compounding Chemotherapy Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Compounding Chemotherapy
Chemotherapy compounding services are provided by pharmacy, hospital, and geriatric care providers based on a commitment to patient care, quality, innovation, and integrity. Chemotherapy is one of the critical cancer treatments that include several chemotherapy drugs such as cancer drugs. The treatment is used to prevent cancer cells from dividing and growing by killing cells in the body that are dividing. It is also used for various types of cancer treatments such as breast cancer, lung cancer, ovarian cancer, myeloma, sarcoma, leukemia, lymphoma, and others. In addition, the increasing prevalence of cancer, the cumulative spending on oncological medicine and research, as well as reimbursements and growing health insurances during the forecast period primarily contribute to the global growth of the chemotherapy market. In addition, the increasing shortage of opioids is expected to increase the demand for compounding chemotherapy worldwide. In addition, several benefits, including easy-to-use drugs, alternative dosage modes for access to expired drugs, and the allergen safety of drugs, are expected to drive future demand. In addition, hospitals and other healthcare providers allow customers to purchase compound drugs.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that European Players will contribute the maximum growth to Global Compounding Chemotherapy market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

B. Braun (Germany), Pfizer (United States), Axter (France), Grifols (Spain), The Metrix Company (United States), Added Pharma (Netherlands), Equashield (United States), Millers Pharmacy (United States), Comecer S.P.A. (Italy), Omnicell (United States), Icon Group (Australia) and Dedalus Group (Italy) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Arxium (Canada), Steriline S.R.L. (Italy) and Loccioni (Italy).

Segmentation Overview
AMA Research has segmented the market of Global Compounding Chemotherapy market by Type (Pharmaceutical Ingredient Alteration (PIA), Currently Unavailable Pharmaceutical Manufacturing (CUPM) and Pharmaceutical Dosage Alteration (PDA)) and Region.



On the basis of geography, the market of Compounding Chemotherapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Delivery Method, the sub-segment i.e. Gravimetric Automated Compounding Device (weight-based) will boost the Compounding Chemotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dose, the sub-segment i.e. Chemotherapeutic will boost the Compounding Chemotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Sterility, the sub-segment i.e. Sterile will boost the Compounding Chemotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising Focus on Improving the Cancer Treatment Procedures for The Worldwide Population and Public Awareness About Various Diseases & Treatment Options

Market Growth Drivers:
The Rising Cancer Prevalence, Increase The Demand for Compounding Chemotherapy Worldwide and Cumulative Spending on Oncology Medicine & Research

Challenges:
Reluctance To Implement the Compounding Process

Restraints:
Increasing Demand for Advanced Therapies Practice and High Cost Associated with Compounding Chemotherapy

Opportunities:
Reimbursements & Growing Health Insurance and A Rise in Government Initiatives

Market Leaders and their expansionary development strategies
In July 2021, Chartwell Pennsylvania, LP partnered with Omnicell to enhance its IV preparation by installing its IVX Workflow sterile compounding technology to manage chemotherapy drug product preparation. This will help Chartwell to enhance safety and dosing accuracy for zero-error medication management.
In November 2020, B. Braun and Grifols announced the partnership to enhance pharmacy production output and therapy safety. The partnership will combine Grifols’ automated compounding portfolio and B. Braun’s Safe Infusion Systems to offer an integrated solution for safe automated drug preparation and delivery. With this partnership, both companies are focusing to roll out their offering in European and other markets., and In October 2019, Equashield announced that it would offer its manual and automated CSTD solutions through direct sales networks in the Netherlands. It is a global manufacturer of closed system transfer systems (CSTD) goods for hazardous substances. Equashield is being sold directly within Europe for the first time.


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Compounding Chemotherapy, Government Regulatory and Research Organizations and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Pharmaceutical Ingredient Alteration (PIA)
  • Currently Unavailable Pharmaceutical Manufacturing (CUPM)
  • Pharmaceutical Dosage Alteration (PDA)
By Delivery Method
  • Gravimetric Automated Compounding Device (weight-based)
  • Volumetric Automated Compounding Device (volume-based)

By Dose
  • Chemotherapeutic
  • Non-Chemotherapeutics

By Sterility
  • Sterile
  • Non-Sterile

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rising Cancer Prevalence
      • 3.2.2. Increase The Demand for Compounding Chemotherapy Worldwide
      • 3.2.3. Cumulative Spending on Oncology Medicine & Research
    • 3.3. Market Challenges
      • 3.3.1. Reluctance To Implement the Compounding Process
    • 3.4. Market Trends
      • 3.4.1. Rising Focus on Improving the Cancer Treatment Procedures for The Worldwide Population
      • 3.4.2. Public Awareness About Various Diseases & Treatment Options
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Compounding Chemotherapy, by Type, Delivery Method, Dose, Sterility and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Compounding Chemotherapy (Value)
      • 5.2.1. Global Compounding Chemotherapy by: Type (Value)
        • 5.2.1.1. Pharmaceutical Ingredient Alteration (PIA)
        • 5.2.1.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
        • 5.2.1.3. Pharmaceutical Dosage Alteration (PDA)
      • 5.2.2. Global Compounding Chemotherapy by: Delivery Method (Value)
        • 5.2.2.1. Gravimetric Automated Compounding Device (weight-based)
        • 5.2.2.2. Volumetric Automated Compounding Device (volume-based)
      • 5.2.3. Global Compounding Chemotherapy by: Dose (Value)
        • 5.2.3.1. Chemotherapeutic
        • 5.2.3.2. Non-Chemotherapeutics
      • 5.2.4. Global Compounding Chemotherapy by: Sterility (Value)
        • 5.2.4.1. Sterile
        • 5.2.4.2. Non-Sterile
      • 5.2.5. Global Compounding Chemotherapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Compounding Chemotherapy (Price)
      • 5.3.1. Global Compounding Chemotherapy by: Type (Price)
  • 6. Compounding Chemotherapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. B. Braun (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Axter (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Grifols (Spain)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. The Metrix Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Added Pharma (Netherlands)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Equashield (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Millers Pharmacy (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Comecer S.P.A. (Italy)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Omnicell (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Icon Group (Australia)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Dedalus Group (Italy)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Compounding Chemotherapy Sale, by Type, Delivery Method, Dose, Sterility and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Compounding Chemotherapy (Value)
      • 7.2.1. Global Compounding Chemotherapy by: Type (Value)
        • 7.2.1.1. Pharmaceutical Ingredient Alteration (PIA)
        • 7.2.1.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
        • 7.2.1.3. Pharmaceutical Dosage Alteration (PDA)
      • 7.2.2. Global Compounding Chemotherapy by: Delivery Method (Value)
        • 7.2.2.1. Gravimetric Automated Compounding Device (weight-based)
        • 7.2.2.2. Volumetric Automated Compounding Device (volume-based)
      • 7.2.3. Global Compounding Chemotherapy by: Dose (Value)
        • 7.2.3.1. Chemotherapeutic
        • 7.2.3.2. Non-Chemotherapeutics
      • 7.2.4. Global Compounding Chemotherapy by: Sterility (Value)
        • 7.2.4.1. Sterile
        • 7.2.4.2. Non-Sterile
      • 7.2.5. Global Compounding Chemotherapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Compounding Chemotherapy (Price)
      • 7.3.1. Global Compounding Chemotherapy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Compounding Chemotherapy: by Type(USD Million)
  • Table 2. Compounding Chemotherapy Pharmaceutical Ingredient Alteration (PIA) , by Region USD Million (2018-2023)
  • Table 3. Compounding Chemotherapy Currently Unavailable Pharmaceutical Manufacturing (CUPM) , by Region USD Million (2018-2023)
  • Table 4. Compounding Chemotherapy Pharmaceutical Dosage Alteration (PDA) , by Region USD Million (2018-2023)
  • Table 5. Compounding Chemotherapy: by Delivery Method(USD Million)
  • Table 6. Compounding Chemotherapy Gravimetric Automated Compounding Device (weight-based) , by Region USD Million (2018-2023)
  • Table 7. Compounding Chemotherapy Volumetric Automated Compounding Device (volume-based) , by Region USD Million (2018-2023)
  • Table 8. Compounding Chemotherapy: by Dose(USD Million)
  • Table 9. Compounding Chemotherapy Chemotherapeutic , by Region USD Million (2018-2023)
  • Table 10. Compounding Chemotherapy Non-Chemotherapeutics , by Region USD Million (2018-2023)
  • Table 11. Compounding Chemotherapy: by Sterility(USD Million)
  • Table 12. Compounding Chemotherapy Sterile , by Region USD Million (2018-2023)
  • Table 13. Compounding Chemotherapy Non-Sterile , by Region USD Million (2018-2023)
  • Table 14. South America Compounding Chemotherapy, by Country USD Million (2018-2023)
  • Table 15. South America Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 16. South America Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 17. South America Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 18. South America Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 19. Brazil Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 20. Brazil Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 21. Brazil Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 22. Brazil Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 23. Argentina Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 24. Argentina Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 25. Argentina Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 26. Argentina Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 27. Rest of South America Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 28. Rest of South America Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 29. Rest of South America Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 30. Rest of South America Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 31. Asia Pacific Compounding Chemotherapy, by Country USD Million (2018-2023)
  • Table 32. Asia Pacific Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 33. Asia Pacific Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 34. Asia Pacific Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 35. Asia Pacific Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 36. China Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 37. China Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 38. China Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 39. China Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 40. Japan Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 41. Japan Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 42. Japan Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 43. Japan Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 44. India Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 45. India Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 46. India Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 47. India Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 48. South Korea Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 49. South Korea Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 50. South Korea Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 51. South Korea Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 52. Taiwan Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 53. Taiwan Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 54. Taiwan Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 55. Taiwan Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 56. Australia Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 57. Australia Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 58. Australia Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 59. Australia Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 60. Rest of Asia-Pacific Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 64. Europe Compounding Chemotherapy, by Country USD Million (2018-2023)
  • Table 65. Europe Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 66. Europe Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 67. Europe Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 68. Europe Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 69. Germany Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 70. Germany Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 71. Germany Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 72. Germany Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 73. France Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 74. France Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 75. France Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 76. France Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 77. Italy Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 78. Italy Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 79. Italy Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 80. Italy Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 81. United Kingdom Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 82. United Kingdom Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 83. United Kingdom Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 84. United Kingdom Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 85. Netherlands Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 86. Netherlands Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 87. Netherlands Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 88. Netherlands Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 89. Rest of Europe Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 90. Rest of Europe Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 91. Rest of Europe Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 92. Rest of Europe Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 93. MEA Compounding Chemotherapy, by Country USD Million (2018-2023)
  • Table 94. MEA Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 95. MEA Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 96. MEA Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 97. MEA Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 98. Middle East Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 99. Middle East Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 100. Middle East Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 101. Middle East Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 102. Africa Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 103. Africa Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 104. Africa Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 105. Africa Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 106. North America Compounding Chemotherapy, by Country USD Million (2018-2023)
  • Table 107. North America Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 108. North America Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 109. North America Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 110. North America Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 111. United States Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 112. United States Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 113. United States Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 114. United States Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 115. Canada Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 116. Canada Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 117. Canada Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 118. Canada Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 119. Mexico Compounding Chemotherapy, by Type USD Million (2018-2023)
  • Table 120. Mexico Compounding Chemotherapy, by Delivery Method USD Million (2018-2023)
  • Table 121. Mexico Compounding Chemotherapy, by Dose USD Million (2018-2023)
  • Table 122. Mexico Compounding Chemotherapy, by Sterility USD Million (2018-2023)
  • Table 123. Compounding Chemotherapy: by Type(USD/Units)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Compounding Chemotherapy: by Type(USD Million)
  • Table 137. Compounding Chemotherapy Pharmaceutical Ingredient Alteration (PIA) , by Region USD Million (2025-2030)
  • Table 138. Compounding Chemotherapy Currently Unavailable Pharmaceutical Manufacturing (CUPM) , by Region USD Million (2025-2030)
  • Table 139. Compounding Chemotherapy Pharmaceutical Dosage Alteration (PDA) , by Region USD Million (2025-2030)
  • Table 140. Compounding Chemotherapy: by Delivery Method(USD Million)
  • Table 141. Compounding Chemotherapy Gravimetric Automated Compounding Device (weight-based) , by Region USD Million (2025-2030)
  • Table 142. Compounding Chemotherapy Volumetric Automated Compounding Device (volume-based) , by Region USD Million (2025-2030)
  • Table 143. Compounding Chemotherapy: by Dose(USD Million)
  • Table 144. Compounding Chemotherapy Chemotherapeutic , by Region USD Million (2025-2030)
  • Table 145. Compounding Chemotherapy Non-Chemotherapeutics , by Region USD Million (2025-2030)
  • Table 146. Compounding Chemotherapy: by Sterility(USD Million)
  • Table 147. Compounding Chemotherapy Sterile , by Region USD Million (2025-2030)
  • Table 148. Compounding Chemotherapy Non-Sterile , by Region USD Million (2025-2030)
  • Table 149. South America Compounding Chemotherapy, by Country USD Million (2025-2030)
  • Table 150. South America Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 151. South America Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 152. South America Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 153. South America Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 154. Brazil Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 155. Brazil Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 156. Brazil Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 157. Brazil Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 158. Argentina Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 159. Argentina Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 160. Argentina Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 161. Argentina Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 162. Rest of South America Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 163. Rest of South America Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 164. Rest of South America Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 165. Rest of South America Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 166. Asia Pacific Compounding Chemotherapy, by Country USD Million (2025-2030)
  • Table 167. Asia Pacific Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 168. Asia Pacific Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 169. Asia Pacific Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 170. Asia Pacific Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 171. China Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 172. China Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 173. China Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 174. China Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 175. Japan Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 176. Japan Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 177. Japan Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 178. Japan Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 179. India Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 180. India Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 181. India Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 182. India Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 183. South Korea Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 184. South Korea Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 185. South Korea Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 186. South Korea Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 187. Taiwan Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 188. Taiwan Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 189. Taiwan Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 190. Taiwan Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 191. Australia Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 192. Australia Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 193. Australia Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 194. Australia Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 195. Rest of Asia-Pacific Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 196. Rest of Asia-Pacific Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 197. Rest of Asia-Pacific Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 198. Rest of Asia-Pacific Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 199. Europe Compounding Chemotherapy, by Country USD Million (2025-2030)
  • Table 200. Europe Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 201. Europe Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 202. Europe Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 203. Europe Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 204. Germany Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 205. Germany Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 206. Germany Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 207. Germany Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 208. France Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 209. France Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 210. France Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 211. France Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 212. Italy Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 213. Italy Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 214. Italy Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 215. Italy Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 216. United Kingdom Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 217. United Kingdom Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 218. United Kingdom Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 219. United Kingdom Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 220. Netherlands Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 221. Netherlands Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 222. Netherlands Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 223. Netherlands Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 224. Rest of Europe Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 225. Rest of Europe Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 226. Rest of Europe Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 227. Rest of Europe Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 228. MEA Compounding Chemotherapy, by Country USD Million (2025-2030)
  • Table 229. MEA Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 230. MEA Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 231. MEA Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 232. MEA Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 233. Middle East Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 234. Middle East Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 235. Middle East Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 236. Middle East Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 237. Africa Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 238. Africa Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 239. Africa Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 240. Africa Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 241. North America Compounding Chemotherapy, by Country USD Million (2025-2030)
  • Table 242. North America Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 243. North America Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 244. North America Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 245. North America Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 246. United States Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 247. United States Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 248. United States Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 249. United States Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 250. Canada Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 251. Canada Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 252. Canada Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 253. Canada Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 254. Mexico Compounding Chemotherapy, by Type USD Million (2025-2030)
  • Table 255. Mexico Compounding Chemotherapy, by Delivery Method USD Million (2025-2030)
  • Table 256. Mexico Compounding Chemotherapy, by Dose USD Million (2025-2030)
  • Table 257. Mexico Compounding Chemotherapy, by Sterility USD Million (2025-2030)
  • Table 258. Compounding Chemotherapy: by Type(USD/Units)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Compounding Chemotherapy: by Type USD Million (2018-2023)
  • Figure 5. Global Compounding Chemotherapy: by Delivery Method USD Million (2018-2023)
  • Figure 6. Global Compounding Chemotherapy: by Dose USD Million (2018-2023)
  • Figure 7. Global Compounding Chemotherapy: by Sterility USD Million (2018-2023)
  • Figure 8. South America Compounding Chemotherapy Share (%), by Country
  • Figure 9. Asia Pacific Compounding Chemotherapy Share (%), by Country
  • Figure 10. Europe Compounding Chemotherapy Share (%), by Country
  • Figure 11. MEA Compounding Chemotherapy Share (%), by Country
  • Figure 12. North America Compounding Chemotherapy Share (%), by Country
  • Figure 13. Global Compounding Chemotherapy: by Type USD/Units (2018-2023)
  • Figure 14. Global Compounding Chemotherapy share by Players 2023 (%)
  • Figure 15. Global Compounding Chemotherapy share by Players (Top 3) 2023(%)
  • Figure 16. Global Compounding Chemotherapy share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. B. Braun (Germany) Revenue, Net Income and Gross profit
  • Figure 19. B. Braun (Germany) Revenue: by Geography 2023
  • Figure 20. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer (United States) Revenue: by Geography 2023
  • Figure 22. Axter (France) Revenue, Net Income and Gross profit
  • Figure 23. Axter (France) Revenue: by Geography 2023
  • Figure 24. Grifols (Spain) Revenue, Net Income and Gross profit
  • Figure 25. Grifols (Spain) Revenue: by Geography 2023
  • Figure 26. The Metrix Company (United States) Revenue, Net Income and Gross profit
  • Figure 27. The Metrix Company (United States) Revenue: by Geography 2023
  • Figure 28. Added Pharma (Netherlands) Revenue, Net Income and Gross profit
  • Figure 29. Added Pharma (Netherlands) Revenue: by Geography 2023
  • Figure 30. Equashield (United States) Revenue, Net Income and Gross profit
  • Figure 31. Equashield (United States) Revenue: by Geography 2023
  • Figure 32. Millers Pharmacy (United States) Revenue, Net Income and Gross profit
  • Figure 33. Millers Pharmacy (United States) Revenue: by Geography 2023
  • Figure 34. Comecer S.P.A. (Italy) Revenue, Net Income and Gross profit
  • Figure 35. Comecer S.P.A. (Italy) Revenue: by Geography 2023
  • Figure 36. Omnicell (United States) Revenue, Net Income and Gross profit
  • Figure 37. Omnicell (United States) Revenue: by Geography 2023
  • Figure 38. Icon Group (Australia) Revenue, Net Income and Gross profit
  • Figure 39. Icon Group (Australia) Revenue: by Geography 2023
  • Figure 40. Dedalus Group (Italy) Revenue, Net Income and Gross profit
  • Figure 41. Dedalus Group (Italy) Revenue: by Geography 2023
  • Figure 42. Global Compounding Chemotherapy: by Type USD Million (2025-2030)
  • Figure 43. Global Compounding Chemotherapy: by Delivery Method USD Million (2025-2030)
  • Figure 44. Global Compounding Chemotherapy: by Dose USD Million (2025-2030)
  • Figure 45. Global Compounding Chemotherapy: by Sterility USD Million (2025-2030)
  • Figure 46. South America Compounding Chemotherapy Share (%), by Country
  • Figure 47. Asia Pacific Compounding Chemotherapy Share (%), by Country
  • Figure 48. Europe Compounding Chemotherapy Share (%), by Country
  • Figure 49. MEA Compounding Chemotherapy Share (%), by Country
  • Figure 50. North America Compounding Chemotherapy Share (%), by Country
  • Figure 51. Global Compounding Chemotherapy: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • B. Braun (Germany)
  • Pfizer (United States)
  • Axter (France)
  • Grifols (Spain)
  • The Metrix Company (United States)
  • Added Pharma (Netherlands)
  • Equashield (United States)
  • Millers Pharmacy (United States)
  • Comecer S.P.A. (Italy)
  • Omnicell (United States)
  • Icon Group (Australia)
  • Dedalus Group (Italy)
Additional players considered in the study are as follows:
Arxium (Canada) , Steriline S.R.L. (Italy) , Loccioni (Italy)
Select User Access Type

Key Highlights of Report


Mar 2024 157 Pages 68 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Compounding Chemotherapy Market Quantitative research analysis
Global Compounding Chemotherapy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as B. Braun (Germany), Pfizer (United States), Axter (France), Grifols (Spain), The Metrix Company (United States), Added Pharma (Netherlands), Equashield (United States), Millers Pharmacy (United States), Comecer S.P.A. (Italy), Omnicell (United States), Icon Group (Australia) and Dedalus Group (Italy) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising Focus on Improving the Cancer Treatment Procedures for The Worldwide Population " is seen as one of major influencing trends for Compounding Chemotherapy Market during projected period 2023-2030.
The Compounding Chemotherapy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Compounding Chemotherapy Market Report?

Have a Query? Click Here

Other Related Reports

Medicare Advantage Comprehensive Study by Type (Health maintenance organizations (HMO), Preferred Provider Organizations (PPO), Special Need Plans and Private Fee For Service, Medical Savings Account...
$ 3450
Viral Gene Therapy Comprehensive Study by Vector Type (Viral Vector {Lentivirus, Adeno-Associated Virus, Retrovirus & Gamma retrovirus, Modified Herpes Simplex, Adenovirus Virus}, Non-Viral Vector {O...
$ 3750
Canker Sores Drug Comprehensive Study by Type (Ointment, Spray, Pills, Patch, Mouthwash), Application (Hospital, Clinics, Drug Store), Packaging Type (Plastic, Aluminum, PE bottles, Glass, Others), F...
$ 3450
Scalp Care Treatment Comprehensive Study by Type (Medicated, Non-Medicated), Drug Type (Branded, Generics), Distribution Channel (Supermarket, Specialty Store, Pharmacy Store, Conventional Stores, On...
$ 3750
Stool Softeners Comprehensive Study by Type (Soft gel capsules, Oral liquids, Tablet, Chewable, Flake, Powder, Others), Distribution Channel (Pharmacy Stores, Online Stores, Hospitals, Clinics, Other...
$ 3450
Coccidiosis Treatment Comprehensive Study by Type (Sulfadimethoxine, Sulfaguanidine, Furazolidone, Trimethoprim/Sulfonamide, Others), Application (Poultry, Dog, Fish, Cat, Cattle, Others), Consumptio...
$ 3450